MENU

LTRN Stock Lantern Pharma (LTRN, $3.18) Stochastic Oscillator left the oversold zone on June 27, 2025

A.I.dvisor
at Tickeron.com
Loading...
LTRN - Lantern Pharma
Stochastic signal
Bullish Trend
Odds of UP Trend
Tickeron
Stochastic signal
Price: $3.18
Daily change: +$0.04 (+1.27%)
Daily volume: 40.3K
Capitalization: $34.3M
Industry: Biotechnology
This is a signal that LTRN's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 71 similar cases where LTRN's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:

LTRN's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for LTRN turned positive on June 24, 2025. Looking at past instances where LTRN's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 71 cases where LTRN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LTRN advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 17, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on LTRN as a result. In of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 10-day moving average for LTRN crossed bearishly below the 50-day moving average on May 27, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LTRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.051) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). LTRN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.247).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LTRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LTRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
LTRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1920 McKinney Avenue
Phone
+1 972 277-1136
Employees
21
Web
https://www.lanternpharma.com